It will partner with Memorial Sloan Kettering Cancer Center to discover and develop CAR-T therapies for multiple myeloma, acute myeloid leukemia and certain solid tumors.
It has exercised an option under its existing research collaboration with Noile-Immune Biotech to exclusively license CAR-T candidates NIB-102 and NIB-103 for solid tumors. It plans to gain regulatory approval for in-human testing of NIB-102 by year-end.
It has exercised an option to exclusively license the Humabody technology from Crescendo Biologics for use in CAR-T therapies. Humabodies are small and can rapidly penetrate and accumulate in tissues and tumors while clearing quickly from circulation minimizing systemic toxicity.
Subscribe for full text news in your inbox